Literature DB >> 6398529

Endemic Lassa fever in Liberia. V. Distribution of Lassa virus activity in Liberia: hospital staff surveys.

J D Frame, J E Yalley-Ogunro, A P Hanson.   

Abstract

Serological testing of hospital personnel by the indirect fluorescent antibody (IFA) technique was used to indicate the distribution of Lassa virus (LV) activity in Liberia. Determination of the places of origin of the staff members as well as the sites of the hospitals indicated that LV is active in throughout Liberia. Prevalences of IFA varied from 3.8% at the J. J. Dossen Hospital on the coast in the south-east to 22.3, 23.5 and 40.4% in Lofa County hospitals inland in the north-west. Rises in LV antibody prevalences, high prevalences and relatively high IFA titres in hospital personnel suggest the LV activity is particularly high in Lofa, Grand Cape Mount and Nimba Counties.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6398529     DOI: 10.1016/0035-9203(84)90012-9

Source DB:  PubMed          Journal:  Trans R Soc Trop Med Hyg        ISSN: 0035-9203            Impact factor:   2.184


  4 in total

Review 1.  The niche of One Health approaches in Lassa fever surveillance and control.

Authors:  Liã Bárbara Arruda; Najmul Haider; Ayodeji Olayemi; David Simons; Deborah Ehichioya; Adesola Yinka-Ogunleye; Rashid Ansumana; Margaret J Thomason; Danny Asogun; Chikwe Ihekweazu; Elisabeth Fichet-Calvet; Richard A Kock
Journal:  Ann Clin Microbiol Antimicrob       Date:  2021-04-24       Impact factor: 3.944

Review 2.  Pathogenesis of Lassa fever.

Authors:  Nadezhda E Yun; David H Walker
Journal:  Viruses       Date:  2012-10-09       Impact factor: 5.048

3.  Risk maps of Lassa fever in West Africa.

Authors:  Elisabeth Fichet-Calvet; David John Rogers
Journal:  PLoS Negl Trop Dis       Date:  2009-03-03

4.  Absence of Nosocomial Transmission of Imported Lassa Fever during Use of Standard Barrier Nursing Methods.

Authors:  Anna Grahn; Andreas Bråve; Thomas Tolfvenstam; Marie Studahl
Journal:  Emerg Infect Dis       Date:  2018-06       Impact factor: 6.883

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.